ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 OutlookGlobeNewsWire • 01/08/26
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025GlobeNewsWire • 10/20/25
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesGlobeNewsWire • 05/12/25
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences ConferenceGlobeNewsWire • 05/02/25
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025GlobeNewsWire • 05/01/25
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of GrowthGlobeNewsWire • 04/14/25
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementGlobeNewsWire • 10/25/24
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementGlobeNewsWire • 10/23/24
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewsWire • 10/07/24
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/10/24
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024GlobeNewsWire • 04/23/24